Gyre Therapeutics, Inc. (GYRE) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
GYRE's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
GYRE Revenue Analysis (2013–2024)
As of March 1, 2026, Gyre Therapeutics, Inc. (GYRE) generated trailing twelve-month (TTM) revenue of $107.3 million, reflecting strong growth of +19.9% year-over-year. The most recent quarter (Q3 2025) recorded $30.6 million in revenue, up 14.2% sequentially.
Looking at the longer-term picture, GYRE's historical revenue data shows a 3-year CAGR of +143.4%. The company achieved its highest annual revenue of $113.5 million in 2023.
Revenue diversification analysis shows GYRE's business is primarily driven by Product (100%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ARGX (+335.2% YoY), CANF (-16.0% YoY), and ABVX (+125.1% YoY), GYRE has underperformed the peer group in terms of revenue growth. Compare GYRE vs ARGX →
Peer Comparison
Compare GYRE's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GYRECurrent | $107M | +19.9% | - | 15.3% | |
| ARGX | $2.2B | +335.2% | +94.6% | -1.0% | |
| CANF | $674,000 | -16.0% | -19.8% | -1206.2% | |
| ABVX | $11M | +125.1% | +457.7% | -1602.9% | |
| KYMR | $39M | -16.7% | +2.9% | -891.3% | |
| TGTX | $329M | +31.0% | +364.6% | 12.7% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $105.8M | -6.8% | $101.9M | 96.3% | $16.2M | 15.3% |
| 2023 | $113.5M | +10.9% | $108.8M | 95.9% | $-67,230,000 | -59.3% |
| 2022 | $102.3M | +1294.0% | $97.5M | 95.3% | $9.2M | 9.0% |
| 2021 | $7.3M | -65.0% | $-332,000 | -4.5% | $-83,726,000 | -1141.0% |
| 2020 | $20.9M | - | $11.8M | 56.3% | $-57,370,000 | -273.9% |
| 2019 | $0 | -100.0% | $-146,000 | - | $-57,277,000 | - |
| 2018 | $6K | -99.4% | $-21,468,000 | -357800.0% | $-33,822,000 | -563700.0% |
| 2017 | $1.0M | +155.1% | $-11,829,000 | -1162.0% | $-21,822,000 | -2143.6% |
| 2016 | $399K | -77.2% | $-10,156,000 | -2545.4% | $-20,418,000 | -5117.3% |
| 2015 | $1.8M | +536.4% | $-4,208,000 | -240.5% | $-13,802,000 | -788.7% |
See GYRE's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GYRE Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GYRE vs AGIO
See how GYRE stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GYRE's revenue growth accelerating or slowing?
GYRE revenue is accelerating at +19.9% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $107M. Growth momentum has increased versus prior periods.
What is GYRE's long-term revenue growth rate?
Gyre Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +19.9% is above this long-term average.
How is GYRE's revenue distributed by segment?
GYRE reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.